COVID-19 vaccine co-developer BioNTech reports June quarter earnings before markets open Monday morning. So do two hot stocks in Cathie Wood's ETF portfolio.
The 1980s were iconic in several ways. The decade was a time of loud fashion like “big hair” and bright colors as well as a time defined by classic entertainment productions, breakdancing, Ronald...
Thursday's top analyst upgrades and downgrades included Agilent Technologies, Carnival, Clorox, Darden Restaurants, Pinduoduo, QuantumScape, Royal Dutch Shell and Williams-Sonoma.
The 2016 movie “Hidden Figures,” which was certainly about racism, was also about the treatment of women in fields that men have dominated throughout history, particularly science, math, and...
Ark Invest Weekly Commentary. Catherine Wood, Ark CEO and CIO, is a non-voting shareholder in 24/7 Wall St. LLC. 24/7 Wall St. editors do not recommend stocks, and these commentary’s are...
These five outstanding stocks are rated Buy, have a least a 4% dividend and offer investors a degree of relative safety. They make sense for growth and income investors while the stock market is...
By Simon Barnett, Analyst The ‘omics revolution describes how technology is transforming our understanding of the fundamental building blocks of life. Starting with the Human Genome Project more...
Rotating from overbought and crowded momentum stocks makes sense now. From a total return standpoint, dividend-paying large-cap pharmaceutical stocks may be one of the best ideas for 2021.
These five stocks are priced right, pay solid and dependable dividends and look to be well positioned for 2021, regardless of who wins the presidential election. They are all attractively priced in a...
President Trump and the First Lady have tested positive for COVID-19. That begs the question, now more than ever, of where we stand with a coronavirus vaccine.
These companies have a very good shot at crossing the finish line first with a COVID-19 vaccine. Even those that won't also have huge product lines and robust pipelines with future drug potential and...
Arrowhead Pharmaceuticals has announced positive interim 24-week liver biopsy results in four subjects from its midstage study of ARO-AAT. Shares rallied on the news early Wednesday. 
These five dividend-paying large-cap pharmaceutical stocks look like outstanding ideas for nervous investors looking for income and a degree of safety. They have come way in from their 52-week...
CureVac stock exploded into the market, more than double its original pricing. Since then, it is up more or less triple its original pricing.
Pfizer and BioNTech made another big step in their fight against COVID-19 by initiating their late-stage study for their lead mRNA vaccine candidate.